Physician profile
Mostafa Farache
NPI 1366646879
$7,086.94
in general payments reported to CMS, 2019-2025
44 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,030 · 2023: $2,219 · 2024: $1,415 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,891 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,891.28 |
| Education | $165.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,222.97 | 2022-2025 | |
| Biogen, INC. | $1,198.79 | 2022-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $396.70 | 2022-2025 | Amyvid, Emgality, Reyvow |
| Catalyst Pharmaceuticals, INC. | $385.92 | 2023-2025 | Fycompa |
| Argenx US, INC. | $331.11 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $288.40 | 2022-2025 | Ultomiris, Soliris |
| Celgene Corporation | $227.91 | 2024-2025 | Zeposia |
| Eisai INC. | $225.89 | 2022-2025 | |
| Sk Life Science, INC. | $203.94 | 2022-2025 | Xcopri |
| Emd Serono, INC. | $187.46 | 2023-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $167.27 | 2024-2025 | |
| Janssen Biotech, INC. | $166.72 | 2025 | |
| Acorda Therapeutics, INC | $155.33 | 2022-2024 | Inbrija, Ampyra |
| Lundbeck LLC | $149.19 | 2022-2025 | Vyepti |
| Banner Life Sciences, LLC | $147.91 | 2023-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.00 | 2023-2025 | Hyqvia |
| Grt US Holding, INC. | $107.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $104.19 | 2022-2025 | Austedo Xr, Austedo |
| Mallinckrodt Hospital Products INC. | $101.64 | 2024-2025 | Acthar |
| Genentech USA, INC. | $91.68 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Novartis Pharmaceuticals Corporation | $85.82 | 2022-2025 | |
| Ucb, INC. | $85.81 | 2022-2025 | Nayzilam |
| Merz Pharmaceuticals, LLC | $85.25 | 2023-2024 | Xeomin |
| Acadia Pharmaceuticals INC | $83.19 | 2023-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $82.26 | 2023-2025 | Crexont, Rytary, Lyvispah |
| Grifols USA, LLC | $72.28 | 2022-2025 | Gamunex-C |
| Genzyme Corporation | $59.25 | 2022-2023 | |
| Livanova USA, INC. | $54.00 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $51.42 | 2022 | |
| Octapharma USA, INC. | $50.95 | 2024-2025 | Panzyga |
| Janssen Pharmaceuticals, INC | $46.43 | 2025 | Spravato |
| Neurelis, INC. | $45.91 | 2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $43.70 | 2025 | Motpoly Xr |
| Neurocrine Biosciences, INC. | $36.51 | 2025 | |
| Corium, LLC | $35.23 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $35.00 | 2023 | Nuedexta |
| Astrazeneca Pharmaceuticals LP | $31.69 | 2024-2025 | Wainua |
| Csl Behring | $21.30 | 2024 | Hizentra |
| Tg Therapeutics, INC. | $20.81 | 2025 | |
| Supernus Pharmaceuticals, INC. | $20.37 | 2022 | |
| Impel Pharmaceuticals INC. | $18.18 | 2023 | Trudhesa |
| Pfizer INC. | $16.67 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.23 | 2023 | Horizant |
| Vanda Pharmaceuticals INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mostafa Farache listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.